These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27058583)

  • 1. Toxic Epidermal Necrolysis with Gastrointestinal Involvement: A Case Report and Review of the Literature.
    Brown CS; Defazio JR; An G; O'Connor A; Whitcomb E; Hart J; Gottlieb LJ
    J Burn Care Res; 2017; 38(1):e450-e455. PubMed ID: 27058583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: a patient who excreted long tubes of dead intestinal epithelium.
    Sugimoto Y; Mizutani H; Sato T; Kawamura N; Ohkouchi K; Shimizu M
    J Dermatol; 1998 Aug; 25(8):533-8. PubMed ID: 9769600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic epidermal necrolysis in Stevens--Johnson syndrome.
    Assaad D; From L; Ricciatti D; Shapero H
    Can Med Assoc J; 1978 Jan; 118(2):154-6. PubMed ID: 757383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Lee HY; Pang SM; Thamotharampillai T
    J Am Acad Dermatol; 2008 Aug; 59(2):352-3. PubMed ID: 18638633
    [No Abstract]   [Full Text] [Related]  

  • 5. Mixed signals: toxic epidermal necrolysis.
    Villano JH; Lovell EO
    Am J Med; 2015 Mar; 128(3):254-6. PubMed ID: 25460525
    [No Abstract]   [Full Text] [Related]  

  • 6. A case of toxic epidermal necrolysis induced by allopurinol with human herpesvirus-6 reactivation.
    Watanabe Y; Matsukura S; Isoda Y; Morita A; Aihara M; Kambara T
    Acta Derm Venereol; 2013 Nov; 93(6):731-2. PubMed ID: 23604033
    [No Abstract]   [Full Text] [Related]  

  • 7. Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States.
    Lu N; Rai SK; Terkeltaub R; Kim SC; Menendez ME; Choi HK
    Semin Arthritis Rheum; 2016 Oct; 46(2):253-258. PubMed ID: 27217070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
    Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J
    Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Stevens-Johnson syndrome following combination drug use of allopurinol, carbamazepine and phenytoin in Taiwan: A case-control study.
    Syu FK; Pan HY; Chuang PC; Huang YS; Cheng CY; Cheng FJ
    J Dermatol; 2018 Sep; 45(9):1080-1087. PubMed ID: 29963717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
    Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
    J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience.
    McCullough M; Burg M; Lin E; Peng D; Garner W
    Burns; 2017 Feb; 43(1):200-205. PubMed ID: 27554629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxic epidermal necrolysis: a review of 20 years of data.
    Marchitto MC; Sung S; Doong J; Chien AL
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e263-e264. PubMed ID: 29314302
    [No Abstract]   [Full Text] [Related]  

  • 13. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allopurinol-induced hypersensitivity syndrome resulting in death].
    Laurisch S; Jaedtke M; Demir R; Sorrentino SA; Kielstein JT; Rennekampff HO; Vogt PM; Meyer GP; Fuchs M; Klein G; Drexler H; Schieffer B; Napp LC
    Med Klin (Munich); 2010 Apr; 105(4):262-6. PubMed ID: 20455046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allopurinol in dermatology.
    Tsai TF; Yeh TY
    Am J Clin Dermatol; 2010; 11(4):225-32. PubMed ID: 20509717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic role of the in vitro drug-induced interferon-gamma release test in Stevens-Johnson syndrome.
    Halevy S; Cohen AD; Livni E
    Int J Dermatol; 1999 Nov; 38(11):835-40. PubMed ID: 10583616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic epidermal necrolysis.
    Wolkenstein P; Revuz J
    Dermatol Clin; 2000 Jul; 18(3):485-95, ix. PubMed ID: 10943543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review.
    Gerull R; Nelle M; Schaible T
    Crit Care Med; 2011 Jun; 39(6):1521-32. PubMed ID: 21358399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis.
    Stern RS; Chan HL
    J Am Acad Dermatol; 1989 Aug; 21(2 Pt 1):317-22. PubMed ID: 2671067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
    Ririe MR; Blaylock RC; Morris SE; Jung JY
    J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.